Plasma asymmetric dimethylarginine, symmetric dimethylarginine, L-Arginine, and nitrite/nitrate concentrations in cats with chronic kidney disease and hypertension

Journal of Veterinary Internal Medicine

Volumn 22, Issue 2, 2008, Pages 317-324

  Jepson, R E ^a   Syme, H M ^a   Vallance, C ^b   Elliott, J ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b WALTHAM CENTRE FOR PET NUTRITION   (United Kingdom)

Author keywords

Amlodipine; Nitric oxide; Proteinuria

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ARGININE; DIMETHYLARGININE; DRUG DERIVATIVE; N,N' DIMETHYLARGININE; N,N'-DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRITE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CAT; CAT DISEASE; CHRONIC KIDNEY FAILURE; HYPERTENSION; VALIDATION STUDY;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARGININE; CAT DISEASES; CATS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; NITRATES; NITRIC OXIDE; NITRITES;

ANIMALIA;

EID: 42449124857     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0075.x     Document Type: Article

References (39)

1. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998;32:958-964.
2. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with renal disease. Kidney Int 2000;58:1261-1266.
3. Schmidt RJ, Yokota S, Tracy TS, et al. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol Renal Physiol 1999;276:F794-F797.
4. Wever R, Boer P, Hijmering M, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999;19:1168-1172.
5. Baylis C, Mitruka B, Deng AY. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278-281.
6. Wagner L, Riggleman A, Erdely A, et al. Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int 2002;62:532-536.
7. Baylis C. Nitric oxide deficiency in chronic renal disease. Eur J Clin Pharmacol 2006;62(Suppl 1):123-130.
8. Zoccali C, Bode-Boger SM, Mallamaci F, et al. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001;358:2113-2117.
9. Fleck C, Janz A, Schweitzer F, et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int 2001;59:S14-S18.
10. Xiao S, Wagner L, Schmidt RJ, et al. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 2001;59:1466-1472.
11. Fliser D. Asymmetric dimethylarginine (ADMA); the silent transition from and 'uraemic toxin' to a global cardiovascular risk molecule. Eur J Clin Invest 2005;35:71-79.
12. Bogle RG, MacAllister RJ, Whitley GS, et al. Induction of NG-monomethyl-L-arginine uptake: A mechanism for differential inhibition of NO synthases. Am J Physiol 1995; 269:C750-C756.
13. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-177.
14. Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006;(Suppl 62):39-44.
15. Reyes A, Purkerson ML, Karl I, et al. Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992;20: 168-176.
16. Node K, Kitakaze M, Yoshikawa H, et al. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997;30:405.
17. Takiuchi S, Fujii H, Kamide K, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertension 2004;17:802-808.
18. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine and endothelial dysfunction in essential hypertension. J Am College Cardiol 2005;46:518-523.
19. Syme HM, Barber PJ, Markwell PJ, et al. Prevalence of systolic hypertension in cats with chronic renal failure at initial evaluation. J Am Vet Med Assoc 2002;220:1799-1804.
20. Stiles J, Polzin DJ, Bistner SI. The prevalence of retinopathy in cats with systemic hypertension and chronic renal failure or hyperthyroidsim. J Am Anim Hosp Assoc 1994;30:564-572.
21. Jepson RE, Broadbelt D, Elliott J, et al. Evaluation of the effects of control of systolic blood pressure on survival in cats with systemic hypertension. J Vet Int Med 2007;21:402-409.
22. Syme HM, Markwell PJ, Pfeiffer D, et al. Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. J Vet Int Med 2006;20:528-535.
23. Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther 2000;292:606-609.
24. Ribeiro MO, Antunes E, Muscara MN, et al. Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension 1995;26:150-155.
25. Menne J, Park JK, Agrawal R, et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J 2006;20:994-996.
26. Belew AM, Barlett T, Brown SA. Evaluation of white-coat effects in cats. J Vet Int Med 1999;13:134-142.
27. Martens-Lobenhoffer J, Bode-Boger SM. Fast and efficient determination of arginine symmetric dimethylarginine and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006;52:488-493.
28. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-2461.
29. Pedersen LG, Tarnow I, Olsen LH, et al. Body size but neither age nor asymptomatic mitral regurgitation influences plasma concentrations of dimethylarginines in dogs. Res Vet Sci 2006;80:336-342.
30. Thuraisingham RC, Yaqoob M. Oxidative consumption of nitric oxide: A potential mediator of uremic vascular disease. Kidney Int 2003;63:S29-S32.
31. Schmidt RJ, Domico J, Samsell LS, et al. Indices of activity of the nitric oxide system in haemodialysis patients. Am J Kidney Dis 1999;34:228-234.
32. Lau T, Owen W, Yu YM, et al. Arginine, citrulline and nitric oxide metabolism in end-stage renal disease patients. J Clin Invest 2000;105:1217-1225.
33. Baylis C, Vallance P. Measurement of nitrite and nitrate levels in plasma and urine - What does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertension 1998;7:59-62.
34. Tsikas D, Gutzki FM, Stichtenoth DO. Circulating and excretory nitrite and nitrate as indicators of nitric oxide synthesis in humans: Methods of analysis. Eur J Clin Pharmacol 2006;62: 51-59.
35. Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003;35:790-796.
36. Praga M, Andrade CF, Luno J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: A double-blind, randomized clnical trial. Nephrol Dial Transplant 2003;18:1806-1813.
37. Janssen JJWM, Gans ROB, van der Meulen J, et al. Comparison between the effects of amlodipine and lisinopril on proteinuria in non-diabetic renal failure. Am J Hypertension 1998;11:1074-1079.
38. Vogel RA. Measurement of endothelial function by brachial artery flow-mediated vasodilation. Am J Cardiol 2001;88:31E-34E.
39. Luis Fuentes V. Endothelial dysfunction in heart disease. In Proceedings of 24th Annual ACVIM Forum, Kentucky, USA, 2006;83-84.